Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bph.12689 http://scihub22266oqcxt.onion/10.1111/bph.12689 C4080969!4080969!24628305     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Pharmacol 2014 ; 171 (13): 3132-45 Nephropedia Template TP {{tp|p=24628305|t=2014. Structure of Class B GPCRs: new horizons for drug discovery |pdf=|usr=}}{{24628305}} gab.com Text Structure of Class B GPCRs: new horizons for drug discovery JO: Br J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=24628305 #FOAvip Class B GPCRs of the secretin family are important drug targets in many human diseases including diabetes, neurodegeneration, cardiovascular disease and psychiatric disorders. X-ray crystal structures for the glucagon receptor and corticotropin-releasing factor receptor 1 have now been published. In this review, we analyse the new structures and how they compare with each other and with Class A and F receptors. We also consider the differences in druggability and possible similarity in the activation mechanisms. Finally, we discuss the potential for the design of small-molecule modulators for these important targets in drug discovery. This new structural insight allows, for the first time, structure-based drug design methods to be applied to Class B GPCRs. Twit Text FOAVip Structure of Class B GPCRs: new horizons for drug discovery ????Br J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=24628305 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24628305 #FOAvip English Wikipedia <ref>{{Cite pmid|24628305}}</ref> Structure of Class B GPCRs: new horizons for drug discovery #MMPMID24628305 Bortolato A; Doré AS; Hollenstein K; Tehan BG; Mason JS; Marshall FH Br J Pharmacol 2014[Jul]; 171 (13): 3132-45 PMID24628305show ga Class B GPCRs of the secretin family are important drug targets in many human diseases including diabetes, neurodegeneration, cardiovascular disease and psychiatric disorders. X-ray crystal structures for the glucagon receptor and corticotropin-releasing factor receptor 1 have now been published. In this review, we analyse the new structures and how they compare with each other and with Class A and F receptors. We also consider the differences in druggability and possible similarity in the activation mechanisms. Finally, we discuss the potential for the design of small-molecule modulators for these important targets in drug discovery. This new structural insight allows, for the first time, structure-based drug design methods to be applied to Class B GPCRs. äStructure of Class B GPCRs: new horizons for drug discovery (epmc).pdf DeepDyve Pubget Overpricing